Headshot of Lewis Cantley

Lewis Cantley, Ph.D.

Professor of Cell Biology (HMS)
Dana-Farber Cancer Institute
TBA--

Lew Cantley is widely known for his many seminal discoveries in signaling and metabolism, including the identification of PI3 kinase and its role in transformation, as well as groundbreaking work unraveling the complexities of protein kinase signaling--his work has had major impact across virtually every aspect of cancer cell biology. For those of you who are new to the department, Lew was a Cell Bio faculty member from 1992-2003 before transitioning to the then newly formed HMS Department of Systems Biology in 2003. In 2012, Lew was recruited to Weill Cornell in New York City, where he served as Director of the Meyer Cancer Center. There, he built a remarkable program focused on the intersection of metabolism and signaling in cancer.

Lew rejoined the Department of Cell Biology at HMS and the DFCI-Cancer Cell Biology in 2022.  

Dana Farber Cancer Institute

Cancer Cell Biology

Faculty Assistant

Development of an intracellularly acting inhibitory peptide selective for PKN.
Authors: Authors: Shiga K, Takayama K, Futaki S, Hutti JE, Cantley LC, Ueki K, Ono Y, Mukai H.
Biochem J
View full abstract on Pubmed
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
Authors: Authors: Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liau LM, Rabinowitz JD, Cantley LC, Thompson CB, Vander Heiden MG, Su SM.
Nature
View full abstract on Pubmed
Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth.
Authors: Authors: Hitosugi T, Kang S, Vander Heiden MG, Chung TW, Elf S, Lythgoe K, Dong S, Lonial S, Wang X, Chen GZ, Xie J, Gu TL, Polakiewicz RD, Roesel JL, Boggon TJ, Khuri FR, Gilliland DG, Cantley LC, Kaufman J, Chen J.
Sci Signal
View full abstract on Pubmed
Getting knit-PI3Ky: PIK3CA mutation status to direct multimodality therapy?
Authors: Authors: Myers AP, Meyerhardt JA, Cantley LC.
Clin Cancer Res
View full abstract on Pubmed
Phosphatidyl inositol 3-kinase signaling in hypothalamic proopiomelanocortin neurons contributes to the regulation of glucose homeostasis.
Authors: Authors: Hill JW, Xu Y, Preitner F, Fukuda M, Cho YR, Luo J, Balthasar N, Coppari R, Cantley LC, Kahn BB, Zhao JJ, Elmquist JK.
Endocrinology
View full abstract on Pubmed
A wortmannin-cetuximab as a double drug.
Authors: Authors: Smith RA, Yuan H, Weissleder R, Cantley LC, Josephson L.
Bioconjug Chem
View full abstract on Pubmed
Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease.
Authors: Authors: Nichols RJ, Dzamko N, Hutti JE, Cantley LC, Deak M, Moran J, Bamborough P, Reith AD, Alessi DR.
Biochem J
View full abstract on Pubmed
Organ-specific lymphangiectasia, arrested lymphatic sprouting, and maturation defects resulting from gene-targeting of the PI3K regulatory isoforms p85alpha, p55alpha, and p50alpha.
Authors: Authors: Mouta-Bellum C, Kirov A, Miceli-Libby L, Mancini ML, Petrova TV, Liaw L, Prudovsky I, Thorpe PE, Miura N, Cantley LC, Alitalo K, Fruman DA, Vary CP.
Dev Dyn
View full abstract on Pubmed
Cancer's insatiable appetite.
Authors: Authors: Locasale JW, Cantley LC, Vander Heiden MG.
Nat Biotechnol
View full abstract on Pubmed
Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling.
Authors: Authors: Gewinner C, Wang ZC, Richardson A, Teruya-Feldstein J, Etemadmoghadam D, Bowtell D, Barretina J, Lin WM, Rameh L, Salmena L, Pandolfi PP, Cantley LC.
Cancer Cell
View full abstract on Pubmed